Search Results - biologics

7 Results

Sort By:

HPMA-based active targeted polymer-anticancer drug conjugates

TECHNOLOGY SUMMARYDrug delivery Pioneer, Dr. Jindřich Kopeček has innovated the next generation of Antibody Drug Conjugates (ADC) with high efficacy tumor targeting and minimal off-target toxicity. The innovative approach involves a controlled living polymerization technique which results in a well-defined semitelechelic maleimide functionalized HPMA...

Published: 9/13/2019 | Inventor(s): Jiyuan Yang, Jindrich (henry) Kopecek, Libin Zhang, Yixin Fang

Keywords(s): Biologics, Therapeutics

Category(s): Therapeutics, Biologics

Novel Peptide for Intervention in Metabolic Syndrome and Obesity

TECHNOLOGY SUMMARYA novel peptide corrects a multitude of abnormalities associated with metabolic syndrome, including obesity, hyperglycemia, and insulin resistance, and is highly potent.BENEFITSNovel biologic agent for intervention in metabolic syndrome and obesity. MARKET OPPORTUNITY The global obesity treatment market is expected to reach USD 15.6...

Published: 4/3/2020 | Inventor(s): Tianxin Yang

Keywords(s): Biologics, Therapeutics

Category(s): Therapeutics, Biologics

T Cell Clone-Specific Immune Checkpoint Therapy

TECHNOLOGY SUMMARYThis technology aims to greatly improve the existing and future immune checkpoint therapies for the treatment of cancer. While current methods of immunotherapy are successful at infiltrating tumor cells and attacking them, they can also begin to attack the hosts’ normal tissues that can be harmful to organs. This invention provides...

Published: 7/18/2019 | Inventor(s): Mingnan Chen, Peng Zhao

Keywords(s):

Category(s): Therapeutics, Biologics

Naonparticle Antibody Conjugate Platform For Targeted Delivery and Tumor Killing

Invention SummaryMonoclonal antibody as a single agent therapy for solid and blood cancers show limited clinical efficacy. High doses are needed which result in undesired adverse immunogenicity and toxicity. Conjugating antibodies to cytotoxic drug show durable clinical response. However ADC designing is complex, with knowledge of linkers, drug and...

Published: 9/13/2019 | Inventor(s): Xinjian Chen, Chengke Luo

Keywords(s): Biologics, Therapeutics

Category(s): Therapeutics, Biologics

Novel Inhibitors of Inflammatory Injury Caused by Neutrophil Extracellular Traps (NETs)

Invention Summary The inventors have developed a novel means of inhibiting NET development and preventing further tissue injury associated with inflammation, both of which will decrease morbidity and mortality. While NET formation is a potent mechanism of killing microbes, there is emerging evidence that NETs mediate vascular and tissue injury in inflammatory...

Published: 9/13/2019 | Inventor(s): Christian Yost, Guy Zimmerman, Andrew Weyrich

Keywords(s): Biologics, Therapeutics

Category(s): Therapeutics, Biologics

Hybridization Mediated Drug Free Macromolecular Therapeutics

Technology Description90% of all non-Hodgkin’s lymphomas (NHL) express CD20. Dr. Kopecek’s team has developed a novel, polymer-based, targeted drug-free therapy. The cytotoxic mechanism of action is via molecular cues that are triggered in the targeted cell (apoptosis). This new paradigm therapy leads to eradication of the tumor and will result...

Published: 5/7/2019 | Inventor(s): Jindrich (henry) Kopecek, Jiyuan Yang, Te-Wei Chu

Keywords(s):

Category(s): Therapeutics, Biologics

Methods for In Vivo Stimulation of Erythropoietin Production

Summary: This invention discloses an approach whereby the administration of a synthetic organic compound specifically induces proliferation of erythropoietin-producing peritubular interstitial cells in the kidney, which results in increased synthesis of erythropoietin. After cessation of treatment with the synthetic compound, there is persistence...

Published: 10/1/2019 | Inventor(s): Bellamkonda Kishore, Jorge Isaac, Christof Westenfelder

Keywords(s): Biologics, Non-Cancer Disease Therapeutics, Therapeutics

Category(s): Therapeutics, Biologics